Roberts Rossela, Neasham Abigail, Lambrinudi Chania, Khan Afshan
School of Psychology, Bangor University, Bangor LL57 2DG, UK.
JRSM Open. 2018 Apr 18;9(4):2054270418758570. doi: 10.1177/2054270418758570. eCollection 2018 Apr.
This study aims to assess the current antipsychotic prescribing trends for the treatment of schizophrenia and to compare them with available guidelines and research evidence.
An observational retrospective quantitative analysis.
Data were collected from the prescribing cost analysis for the period between 2007 and 2014, including all drugs from the British National Formulary 4.2.1 and 4.2.2. Prescriptions were included from primary and secondary healthcare settings in England and Wales.
None.
Defined daily doses of antipsychotics were used to compare popularity of individual drugs and classes of antipsychotics.
There is a consistent increase in the proportion of atypical antipsychotics prescribed, compared to typical antipsychotics, between 2007 and 2014, with atypicals accounting for 79.9% of total antipsychotics prescribed in 2014.
The consistent popularity of atypical antipsychotics is not concordant with the current National Institute for Health and Care Excellence guidelines for the treatment of schizophrenia or the most recent research evidence.
本研究旨在评估目前治疗精神分裂症的抗精神病药物处方趋势,并将其与现有指南及研究证据进行比较。
一项观察性回顾性定量分析。
数据收集自2007年至2014年期间的处方成本分析,包括《英国国家处方集》4.2.1和4.2.2中的所有药物。处方来自英格兰和威尔士的初级和二级医疗保健机构。
无。
使用抗精神病药物的限定日剂量来比较各药物及各类抗精神病药物的受欢迎程度。
与典型抗精神病药物相比,2007年至2014年间非典型抗精神病药物的处方比例持续增加,2014年非典型药物占抗精神病药物处方总量的79.9%。
非典型抗精神病药物持续受到欢迎,这与当前英国国家卫生与临床优化研究所治疗精神分裂症的指南或最新研究证据不一致。